Clinical trial
Somatropin Treatment to Final Height in Turner Syndrome
NCT00191113 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191113 |
|---|---|
| Title | Somatropin Treatment to Final Height in Turner Syndrome |
| Official title | Humatrope Treatment to Final Height in Turner's Syndrome |
| Acronym | GDCT |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Turner Syndrome |
| Intervention type | Drug |
| Interventions | Somatropin, Ethinyl estradiol, Medroxyprogesterone acetate |
| Enrollment | 154 |
| Start date | Feb 1, 1989 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 27, 2010 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: